يعرض 121 - 130 نتائج من 879 نتيجة بحث عن '"Castellano, Daniel"', وقت الاستعلام: 1.26s تنقيح النتائج
  1. 121
    دورية أكاديمية
  2. 122
    دورية أكاديمية
  3. 123
    دورية أكاديمية
  4. 124
  5. 125
    دورية أكاديمية

    المساهمون: 1Englander Institute for Precision Medicine, Weill Cornell Medicine, Meyer Cancer Center, New York, NY, USA. Electronic address: cns9006@med.cornell.edu. 212 de Octubre University Hospital, Madrid, Spain. 3The Institute of Cancer Research and the Royal Marsden Hospital, London, UK. 4Gustave Roussy Institute and University of Paris Saclay, Villejuif, France. 5Institute de Recherche Clinique, Université Catholique de Louvain, Brussels, Belgium. 6Department of Urology, Asklepios Tumorzentrum Hamburg, Asklepios Klinik Altona, Hamburg, Germany. 7Department of Urology, Medical University of Vienna, Vienna, Austria. 8Jean Godinot Institute, Reims, France. 9Alexandra Hospital, National and Kapodistrian University of Athens, Athens, Greece. 10Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain. 11Azienda Ospedaliera Universitaria Integrata (AOUI), Verona, Italy, Fondazione Policlinico Agostino Gemelli IRCCS, Rome, Italy. 12Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic. 13Landspitali University Hospital, Reykjavik, Iceland. 14Foch Hospital, Suresnes, France. 15Studienpraxis Urologie, Nürtingen, Germany. 16Hôpital D'Instruction des Armées, Bégin, Saint Mandé, France. 17Sanofi, Global Medical Oncology, Cambridge, MA, USA. 18Sanofi, Europe Medical Oncology, Paris, France. 19Erasmus University Hospital, Rotterdam, The Netherlands.

    المصدر: European urology ; 80 ; 4 ; 497 ; 506 ; Switzerland

    العلاقة: https://www.sciencedirect.com/science/article/pii/S0302283821018625?via%3DihubTest; Sternberg CN, Castellano D, de Bono J, et al. Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study. Eur Urol. 2021;80(4):497-506. doi:10.1016/j.eururo.2021.06.021; http://hdl.handle.net/2336/622020Test; European urology

  6. 126
    دورية أكاديمية

    المساهمون: 3405580

    العلاقة: JOURNAL OF CLINICAL ONCOLOGY; Csoszi T., Powles T., Alva A. S. , Castellano D. E. , Ozguroglu M., O'Donnell P. H. , Loriot Y., Hahn N. M. , Flechon A., Rodriguez-Vida A., et al., "First-line pembrolizumab in advanced urothelial carcinoma: Clinical parameters associated with efficacy in the phase 2 KEYNOTE-052 and phase 3 KEYNOTE-361 trials.", JOURNAL OF CLINICAL ONCOLOGY, cilt.40, sa.6, 2022; av_e1a3a425-2bc3-4cc8-ae04-040342655597; vv_1032021; http://hdl.handle.net/20.500.12627/185061Test; https://doi.org/10.1200/jco.2022.40.6_suppl.521Test; 40

  7. 127
    دورية أكاديمية

    المصدر: Hamut´ay, ISSN 2313-7878, Vol. 9, Nº. 2, 2022 (Ejemplar dedicado a: Hamut'ay), pags. 41-47

    وصف الملف: application/pdf

    العلاقة: https://dialnet.unirioja.es/servlet/oaiart?codigo=8767228Test; (Revista) ISSN 2313-7878

  8. 128
    دورية أكاديمية

    المصدر: Journal of Cancer Research and Clinical Oncology ; volume 148, issue 5, page 1097-1105 ; ISSN 0171-5216 1432-1335

    مصطلحات موضوعية: Cancer Research, Oncology, General Medicine

  9. 129
  10. 130
    دورية أكاديمية